November 2023
1. BRENNHOFER SA, Platts-Mills JA, Lewnard JA, Liu J, et al
   Burden of diarrhea and antibiotic use among children in low-resource settings preventable by Shigella vaccination: A simulation study.
   PLoS Med. 2023;20:e1004271.
   

   >> Share

   
   September 2023
2. WATKINSON RE, Williams R, Gillibrand S, Munford L, et al
   Evaluating socioeconomic inequalities in influenza vaccine uptake during the COVID-19 pandemic: A cohort study in Greater Manchester, England.
   PLoS Med. 2023;20:e1004289.
   

   >> Share

   
   July 2023
3. XIONG X, Lui DTW, Chung MSH, Au ICH, et al
   Incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong: A population-based cohort study.
   PLoS Med. 2023;20:e1004274.
   

   >> Share

   
   
4. PORTNOY A, Arcand JL, Clark RA, Weerasuriya CK, et al
   The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries: A modeling study.
   PLoS Med. 2023;20:e1004252.
   

   >> Share

   
   June 2023
5. STOWE J, Miller E, Andrews N, Whitaker HJ, et al
   Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.
   PLoS Med. 2023;20:e1004245.
   

   >> Share

   
   
6. QIN K, Honjo K, Sherrill-Mix S, Liu W, et al
   Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.
   PLoS Med. 2023;20:e1004157.
   

   >> Share

   
   May 2023
7. KUMAR CK, Sands K, Walsh TR, O'Brien S, et al
   Global, regional, and national estimates of the impact of a maternal Klebsiella pneumoniae vaccine: A Bayesian modeling analysis.
   PLoS Med. 2023;20:e1004239.
   

   >> Share

   
   March 2023
8. MEMIRIE ST, Tolla MT, Rumpler E, Sato R, et al
   Out-of-pocket expenditures and financial risks associated with treatment of vaccine-preventable diseases in Ethiopia: A cross-sectional costing analysis.
   PLoS Med. 2023;20:e1004198.
   

   >> Share

   
   February 2023
9. NORDSTROM P, Ballin M, Nordstrom A
   Safety and effectiveness of monovalent COVID-19 mRNA vaccination and risk factors for hospitalisation caused by the omicron variant in 0.8 million adolescents: A nationwide cohort study in Sweden.
   PLoS Med. 2023;20:e1004127.
   

   >> Share

   
   January 2023
10. DIMITROVA A, Carrasco-Escobar G, Richardson R, Benmarhnia T, et al
    Essential childhood immunization in 43 low- and middle-income countries: Analysis of spatial trends and socioeconomic inequalities in vaccine coverage.
    PLoS Med. 2023;20:e1004166.
    

    >> Share

    
    
11. WAN J, Cazer CL, Clarkberg ME, Henderson SG, et al
    Booster vaccination protection against SARS-CoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study.
    PLoS Med. 2023;20:e1004153.
    

    >> Share

    
    
12. HENSLEY KS, Jongkees MJ, Geers D, GeurtsvanKessel CH, et al
    Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
    PLoS Med. 2023;20:e1004159.
    

    >> Share

    
    
13. PORTNOY A, Clark RA, Quaife M, Weerasuriya CK, et al
    The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study.
    PLoS Med. 2023;20:e1004155.
    

    >> Share

    
    
14. BOR J, Assoumou SA, Lane K, Diaz Y, et al
    Inequities in COVID-19 vaccine and booster coverage across Massachusetts ZIP codes after the emergence of Omicron: A population-based cross-sectional study.
    PLoS Med. 2023;20:e1004167.
    

    >> Share

    
    
15. CERQUEIRA-SILVA T, Shah SA, Robertson C, Sanchez M, et al
    Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case-control study.
    PLoS Med. 2023;20:e1004156.
    

    >> Share

    
    December 2022
16. LIND ML, Robertson AJ, Silva J, Warner F, et al
    Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case-control analysis.
    PLoS Med. 2022;19:e1004136.
    

    >> Share

    
    November 2022
17. BABOUEE FLURY B, Gusewell S, Egger T, Leal O, et al
    Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
    PLoS Med. 2022;19:e1004125.
    

    >> Share

    
    
18. NIELSEN KF, Moustsen-Helms IR, Schelde AB, Gram MA, et al
    Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    PLoS Med. 2022;19:e1004037.
    

    >> Share

    
    October 2022
19. HENSLEY KS, Jongkees MJ, Geers D, GeurtsvanKessel CH, et al
    Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
    PLoS Med. 2022;19:e1003979.
    

    >> Share

    
    September 2022
20. GRAM MA, Emborg HD, Schelde AB, Friis NU, et al
    Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    PLoS Med. 2022;19:e1003992.
    

    >> Share

    
    August 2022
21. MODY A, Bradley C, Redkar S, Fox B, et al
    Quantifying inequities in COVID-19 vaccine distribution over time by social vulnerability, race and ethnicity, and location: A population-level analysis in St. Louis and Kansas City, Missouri.
    PLoS Med. 2022;19:e1004048.
    

    >> Share

    
    July 2022
22. HERNANDEZ I, Dickson S, Tang S, Gabriel N, et al
    Disparities in distribution of COVID-19 vaccines across US counties: A geographic information system-based cross-sectional study.
    PLoS Med. 2022;19:e1004069.
    

    >> Share

    
    
23. MASSARI M, Spila Alegiani S, Morciano C, Spuri M, et al
    Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
    PLoS Med. 2022;19:e1004056.
    

    >> Share

    
    June 2022
24. TAKUVA S, Takalani A, Seocharan I, Yende-Zuma N, et al
    Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial.
    PLoS Med. 2022;19:e1004024.
    

    >> Share

    
    
25. WONG CKH, Lau KTK, Xiong X, Au ICH, et al
    Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    PLoS Med. 2022;19:e1004018.
    

    >> Share

    
    May 2022
26. JIN P, Guo X, Chen W, Ma S, et al
    Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
    PLoS Med. 2022;19:e1003953.
    

    >> Share

    
    
27. MARTIN CA, Pan D, Melbourne C, Teece L, et al
    Risk factors associated with SARS-CoV-2 infection in a multiethnic cohort of United Kingdom healthcare workers (UK-REACH): A cross-sectional analysis.
    PLoS Med. 2022;19:e1004015.
    

    >> Share

    
    
28. PEARSON CAB, Bozzani F, Procter SR, Davies NG, et al
    Correction: COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.
    PLoS Med. 2022;19:e1003990.
    

    >> Share

    
    
29. VAN GILS MJ, Lavell A, van der Straten K, Appelman B, et al
    Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study.
    PLoS Med. 2022;19:e1003991.
    

    >> Share

    
    
30. QIAN G, Toizumi M, Clifford S, Le LT, et al
    Association of pneumococcal carriage in infants with the risk of carriage among their contacts in Nha Trang, Vietnam: A nested cross-sectional survey.
    PLoS Med. 2022;19:e1004016.
    

    >> Share

    
    April 2022
31. FOO D, Sarna M, Pereira G, Moore HC, et al
    Prenatal influenza vaccination and allergic and autoimmune diseases in childhood: A longitudinal, population-based linked cohort study.
    PLoS Med. 2022;19:e1003963.
    

    >> Share

    
    
32. WATKINSON RE, Williams R, Gillibrand S, Sanders C, et al
    Correction: Ethnic inequalities in COVID-19 vaccine uptake and comparison to seasonal influenza vaccine uptake in Greater Manchester, UK: A cohort study.
    PLoS Med. 2022;19:e1003982.
    

    >> Share

    
    March 2022
33. WATKINSON RE, Williams R, Gillibrand S, Sanders C, et al
    Ethnic inequalities in COVID-19 vaccine uptake and comparison to seasonal influenza vaccine uptake in Greater Manchester, UK: A cohort study.
    PLoS Med. 2022;19:e1003932.
    

    >> Share

    
    February 2022
34. SAAKSVUORI L, Betsch C, Nohynek H, Salo H, et al
    Information nudges for influenza vaccination: Evidence from a large-scale cluster-randomized controlled trial in Finland.
    PLoS Med. 2022;19:e1003919.
    

    >> Share

    
    
35. 
    Vaccine equity: A fundamental imperative in the fight against COVID-19.
    PLoS Med. 2022;19:e1003948.
    

    >> Share

    
    
36. KERR S, Joy M, Torabi F, Bedston S, et al
    First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales.
    PLoS Med. 2022;19:e1003927.
    

    >> Share

    
    
37. WHITELEY WN, Ip S, Cooper JA, Bolton T, et al
    Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England.
    PLoS Med. 2022;19:e1003926.
    

    >> Share

    
    
38. MCQUAID F, Mulholland R, Sangpang Rai Y, Agrawal U, et al
    Uptake of infant and preschool immunisations in Scotland and England during the COVID-19 pandemic: An observational study of routinely collected data.
    PLoS Med. 2022;19:e1003916.
    

    >> Share

    
    January 2022
39. GENTILE I, Schiano Moriello N
    COVID-19 prophylaxis in immunosuppressed patients: Beyond vaccination.
    PLoS Med. 2022;19:e1003917.
    

    >> Share

    
    
40. ANYWAINE Z, Barry H, Anzala O, Mutua G, et al
    Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.
    PLoS Med. 2022;19:e1003865.
    

    >> Share

    
    December 2021
41. GRAM MA, Nielsen J, Schelde AB, Nielsen KF, et al
    Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.
    PLoS Med. 2021;18:e1003874.
    

    >> Share

    
    
42. PETERSEN M, Schwab J, Havlir DV
    SARS-CoV-2 vaccine boosters: The time to act is now.
    PLoS Med. 2021;18:e1003882.
    

    >> Share

    
    November 2021
43. MARTIN CA, Marshall C, Patel P, Goss C, et al
    SARS-CoV-2 vaccine uptake in a multi-ethnic UK healthcare workforce: A cross-sectional study.
    PLoS Med. 2021;18:e1003823.
    

    >> Share

    
    
44. BHANU C, Gopal DP, Walters K, Chaudhry UAR, et al
    Vaccination uptake amongst older adults from minority ethnic backgrounds: A systematic review.
    PLoS Med. 2021;18:e1003826.
    

    >> Share

    
    October 2021
45. PEARSON CAB, Bozzani F, Procter SR, Davies NG, et al
    COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.
    PLoS Med. 2021;18:e1003815.
    

    >> Share

    
    
46. FORMICA N, Mallory R, Albert G, Robinson M, et al
    Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
    PLoS Med. 2021;18:e1003769.
    

    >> Share

    
    
47. ISANAKA S, Garba S, Plikaytis B, McNeal MM, et al
    Correction: Immunogenicity of an oral rotavirus vaccine administered with prenatal nutritional support in Niger: A cluster randomized clinical trial.
    PLoS Med. 2021;18:e1003776.
    

    >> Share

    
    
48. BARRY H, Mutua G, Kibuuka H, Anywaine Z, et al
    Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.
    PLoS Med. 2021;18:e1003813.
    

    >> Share

    
    
49. GENG EH, Reid MJA, Goosby E, Abdool-Karim Q, et al
    COVID-19 and global equity for health: The good, the bad, and the wicked.
    PLoS Med. 2021;18:e1003797.
    

    >> Share

    
    September 2021
50. NAGATA JM, Epstein A, Ganson KT, Benmarhnia T, et al
    Drought and child vaccination coverage in 22 countries in sub-Saharan Africa: A retrospective analysis of national survey data from 2011 to 2019.
    PLoS Med. 2021;18:e1003678.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share